Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Oct 14;311(7011):977–980. doi: 10.1136/bmj.311.7011.977

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group.

C C McDonald 1, F E Alexander 1, B W Whyte 1, A P Forrest 1, H J Stewart 1
PMCID: PMC2550987  PMID: 7580638

Abstract

OBJECTIVE--To determine any cardiac or vascular morbidity associated with long term treatment with tamoxifen given after mastectomy for primary breast cancer. DESIGN--Cohort study using linkage between database of a randomised trial and statistics of Scottish hospital inpatients to identify episodes of cardiac and vascular morbidity. SETTING--NHS hospitals in Scotland. SUBJECTS--1312 women who had undergone mastectomy for breast cancer and who were randomised either to a treatment group to receive adjuvant tamoxifen or to a control group to be given tamoxifen only on first relapse of disease. Maximum duration of tamoxifen treatment was 14 years. Total woman years of follow up were 9943. MAIN OUTCOME MEASURES--Randomised and observational comparisons of risk (expressed as hazard ratios) of myocardial infarction, other cardiac event, cerebrovascular disease, or thromboembolic event according to treatment allocated and between nonusers, former users, and current users of tamoxifen. RESULTS--Use of tamoxifen was associated with lower rates of myocardial infarction. Hazard ratio for women in control group was 1.92 (95% confidence interval 0.99 to 3.73) compared with women allocated to adjuvant treatment. The association was stronger for current use: hazard ratio for non-users was 3.49 (1.52 to 8.03) compared with current users. Current users of tamoxifen, however, had higher rates of thromboembolic events:hazard ratio for non-users was 0.40 (0.18 to 0.90) compared with current users. CONCLUSIONS--Our results provide further evidence that tamoxifen reduces the risk of myocardial infarction. Thromboembolic events should be carefully monitored in trials of tamoxifen, particularly those of prophylactic treatment, in which tamoxifen is given to healthy women.

Full text

PDF
977

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., De Stavola B. L. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med. 1994 Feb 28;13(4):301–341. doi: 10.1002/sim.4780130402. [DOI] [PubMed] [Google Scholar]
  2. Bruning P. F., Bonfrer J. M., Hart A. A., de Jong-Bakker M., Linders D., van Loon J., Nooyen W. J. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988 Oct;58(4):497–499. doi: 10.1038/bjc.1988.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cuzick J., Allen D., Baum M., Barrett J., Clark G., Kakkar V., Melissari E., Moniz C., Moore J., Parsons V. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer. 1992;29A(1):15–21. doi: 10.1016/0959-8049(93)90568-z. [DOI] [PubMed] [Google Scholar]
  4. Dewar J. A., Horobin J. M., Preece P. E., Tavendale R., Tunstall-Pedoe H., Wood R. A. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992 Jul 25;305(6847):225–226. doi: 10.1136/bmj.305.6847.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jordan V. C., Fritz N. F., Tormey D. C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 1987 Aug 15;47(16):4517–4519. [PubMed] [Google Scholar]
  6. Love R. R., Newcomb P. A., Wiebe D. A., Surawicz T. S., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990 Aug 15;82(16):1327–1332. doi: 10.1093/jnci/82.16.1327. [DOI] [PubMed] [Google Scholar]
  7. McDonald C. C., Stewart H. J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991 Aug 24;303(6800):435–437. doi: 10.1136/bmj.303.6800.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rutqvist L. E., Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993 Sep 1;85(17):1398–1406. doi: 10.1093/jnci/85.17.1398. [DOI] [PubMed] [Google Scholar]
  9. Saphner T., Tormey D. C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991 Feb;9(2):286–294. doi: 10.1200/JCO.1991.9.2.286. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES